Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Cowen starts scPharmaceuticals at Outperform on Furoscix potential » 09:07
12/01/22
12/01
09:07
12/01/22
09:07
SCPH

scPharmaceuticals

$7.33 /

+0.17 (+2.37%)

Cowen analyst Ken…

Cowen analyst Ken Cacciatore initiated coverage of scPharmaceuticals with an Outperform rating and $25 price target. scPharmaceuticals' lead product, Furoscix, was approved in October and provides a subcutaneous treatment option to the 2M fluid overload episodes experienced by heart failure patients in need of IV diuretics, noted Cacciatore. His price target "conservatively" assumes peak Furoscix sales of $500M-plus by 2033-2034, or about 15% share of the addressable acute heart failure episodes, the analyst tells investors.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

12/01/22 Cowen
scPharmaceuticals initiated with an Outperform at Cowen
11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

  • 22
    Nov
SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

Initiation
scPharmaceuticals initiated with an Outperform at Cowen » 06:02
12/01/22
12/01
06:02
12/01/22
06:02
SCPH

scPharmaceuticals

$7.33 /

+0.17 (+2.37%)

Cowen analyst Ken…

Cowen analyst Ken Cacciatore initiated coverage of scPharmaceuticals with an Outperform rating and $25 price target.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

  • 22
    Nov
SCPH scPharmaceuticals
$7.33 /

+0.17 (+2.37%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
11/22/22
11/22
08:56
11/22/22
08:56
WBA

Walgreens Boots Alliance

$40.60 /

+0.86 (+2.16%)

, GME

GameStop

$25.17 /

-2.43 (-8.80%)

, ADI

Analog Devices

$159.23 /

-2.56 (-1.58%)

, BBY

Best Buy

$70.82 /

-1.225 (-1.70%)

, AEO

American Eagle

$13.02 /

+0.085 (+0.66%)

, MDT

Medtronic

$82.26 /

+0.98 (+1.21%)

, DLTR

Dollar Tree

$165.23 /

+1.98 (+1.21%)

, GMDA

Gamida Cell

$1.79 /

+0.02 (+1.13%)

, SCPH

scPharmaceuticals

$6.09 /

-0.235 (-3.72%)

, JACK

Jack in the Box

$84.99 /

-0.22 (-0.26%)

Check out this morning's…

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

11/22/22 Cowen
Walgreens upgraded to Outperform on services transition at Cowen
11/22/22 Cowen
Walgreens Boots Alliance upgraded to Outperform from Market Perform at Cowen
11/18/22 JPMorgan
Walgreens Boots Alliance upgraded to Overweight from Neutral at JPMorgan
11/11/22 Deutsche Bank
Walgreens upgraded to Buy with $50 target at Deutsche Bank
GME GameStop
$25.17 /

-2.43 (-8.80%)

10/13/22 Jefferies
GameStop transferred with a Hold at Jefferies
08/16/22 B. Riley
B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell
07/22/22 Wedbush
GameStop price target lowered to $7.50 from $30 at Wedbush
05/26/22 Wedbush
Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns
ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

11/15/22 Credit Suisse
Analog Devices assumed with a Neutral at Credit Suisse
10/24/22 Barclays
Analog Devices downgraded to Equal Weight from Overweight at Barclays
10/18/22 Deutsche Bank
Analog Devices price target lowered to $155 from $170 at Deutsche Bank
10/11/22 Cowen
Cowen starts Analog Devices at Outperform, says 'built to last' beyond cycle
BBY Best Buy
$70.82 /

-1.225 (-1.70%)

10/19/22 Evercore ISI
Best Buy downgraded to In Line from Outperform at Evercore ISI
10/19/22 Evercore ISI
Best Buy downgraded to In Line from Outperform at Evercore ISI
08/31/22 Truist
Best Buy price target raised to $69 from $67 at Truist
08/31/22 DA Davidson
Best Buy price target lowered to $99 from $110 at DA Davidson
AEO American Eagle
$13.02 /

+0.085 (+0.66%)

09/16/22 JPMorgan
American Eagle price target raised to $13 from $12 at JPMorgan
09/09/22 Barclays
American Eagle price target raised to $11 from $10 at Barclays
09/08/22 Cowen
American Eagle price target lowered to $11 from $13 at Cowen
09/08/22 Citi
American Eagle price target lowered to $10 from $13 at Citi
MDT Medtronic
$82.26 /

+0.98 (+1.21%)

11/16/22 Deutsche Bank
Medtronic downgraded to Hold from Buy at Deutsche Bank
10/24/22 Piper Sandler
Medtronic spinoff an 'incremental positive' for company, says Piper Sandler
10/18/22 Barclays
Barclays starts medical devices with Positive view, Boston Scientific top pick
10/17/22 Barclays
Medtronic initiated with an Equal Weight at Barclays
DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

11/16/22 OTR Global
Dollar Tree view upgraded to Positive from Mixed at OTR Global
09/06/22 JPMorgan
Dollar Tree price target raised to $176 from $171 at JPMorgan
08/29/22 Deutsche Bank
Dollar Tree price target lowered to $163 from $185 at Deutsche Bank
08/26/22 Truist
Dollar Tree price target lowered to $168 from $178 at Truist
GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

11/15/22 Oppenheimer
Gamida Cell price target lowered to $10 from $15 at Oppenheimer
10/02/22 Piper Sandler
Piper Sandler keeps Overweight on Gamida Cell, lowers price target to $7
08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

11/08/22 Deutsche Bank
Jack in the Box downgraded to Hold from Buy at Deutsche Bank
09/21/22 Wolfe Research
Jack in the Box initiated with a Peer Perform at Wolfe Research
09/12/22 Wedbush
Wedbush ups Jack in the Box price target to $115, adds to Best Ideas List
08/30/22 Wedbush
Jack in the Box 'most exposed' to direct impact from AB 257, says Wedbush
WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

  • 22
    Nov
  • 28
    Sep
WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

Syndicate
scPharmaceuticals 6.62M share Spot Secondary priced at $5.25 » 08:29
11/22/22
11/22
08:29
11/22/22
08:29
SCPH

scPharmaceuticals

$6.09 /

-0.235 (-3.72%)

SVB Securities and Cowen…

SVB Securities and Cowen acted as joint book running managers for the offering.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

  • 22
    Nov
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

Hot Stocks
scPharmaceuticals announces pricing of $50M public offering » 08:21
11/22/22
11/22
08:21
11/22/22
08:21
SCPH

scPharmaceuticals

$6.09 /

-0.235 (-3.72%)

scPharmaceuticals…

scPharmaceuticals announced the pricing of an underwritten public offering of 6,620,000 shares of its common stock at a public offering price of $5.25 per share and, to an investor in lieu of common stock, a prefunded warrant to purchase up to 2,905,000 shares of common stock at a purchase price of $5.249 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrant. The prefunded warrant has an exercise price of $0.001 per share. All of the shares and the prefunded warrant are being offered by scPharmaceuticals. The offering is expected to close on November 25, 2022, subject to the satisfaction of customary closing conditions. SVB Securities and Cowen are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Maxim Group LLC are acting as co-managers for the offering.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

  • 22
    Nov
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

On The Fly
Fly Intel: After-Hours Movers » 18:31
11/21/22
11/21
18:31
11/21/22
18:31
STAF

Staffing 360 Solutions

$2.69 /

-0.06 (-2.18%)

, SYM

Symbotic

$9.95 /

+0.875 (+9.64%)

, A

Agilent

$144.82 /

-1.4 (-0.96%)

, ZM

Zoom Video

$80.30 /

-1.38 (-1.69%)

, SCPH

scPharmaceuticals

$6.09 /

-0.235 (-3.72%)

Check out this evening's…

ShowHide Related Items >><<
ZM Zoom Video
$80.30 /

-1.38 (-1.69%)

SYM Symbotic
$9.95 /

+0.875 (+9.64%)

STAF Staffing 360 Solutions
$2.69 /

-0.06 (-2.18%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

A Agilent
$144.82 /

-1.4 (-0.96%)

STAF Staffing 360 Solutions
$2.69 /

-0.06 (-2.18%)

07/05/22 Greenridge
Staffing 360 Solutions price target lowered to $20 from $45 at Greenridge
SYM Symbotic
$9.95 /

+0.875 (+9.64%)

09/19/22 UBS
Symbotic initiated with a Buy at UBS
08/03/22 Citi
Symbotic price target raised to $21 from $15 at Citi
08/02/22 Northland
Symbotic price target raised to $20 from $16 at Northland
08/02/22 Deutsche Bank
Symbotic price target raised to $22 from $19 at Deutsche Bank
A Agilent
$144.82 /

-1.4 (-0.96%)

08/24/22 Credit Suisse
Agilent initiated with an Outperform at Credit Suisse
08/17/22 BofA
Agilent price target raised to $155 from $148 at BofA
08/17/22 Citi
Agilent price target raised to $145 from $140 at Citi
08/17/22 Baird
Agilent price target raised to $160 from $155 at Baird
ZM Zoom Video
$80.30 /

-1.38 (-1.69%)

11/18/22 Baird
Zoom Video price target lowered to $100 from $125 at Baird
11/16/22 Citi
Zoom Video price target lowered to $72 from $76 at Citi
11/09/22 MKM Partners
Zoom Video price target lowered to $100 from $125 at MKM Partners
11/09/22 Stifel
Zoom Video price target lowered to $80 from $90 at Stifel
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
ZM Zoom Video
$80.30 /

-1.38 (-1.69%)

SYM Symbotic
$9.95 /

+0.875 (+9.64%)

STAF Staffing 360 Solutions
$2.69 /

-0.06 (-2.18%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

A Agilent
$144.82 /

-1.4 (-0.96%)

  • 22
    Nov
ZM Zoom Video
$80.30 /

-1.38 (-1.69%)

ZM Zoom Video
$80.30 /

-1.38 (-1.69%)

SYM Symbotic
$9.95 /

+0.875 (+9.64%)

A Agilent
$144.82 /

-1.4 (-0.96%)

ZM Zoom Video
$80.30 /

-1.38 (-1.69%)

SYM Symbotic
$9.95 /

+0.875 (+9.64%)

A Agilent
$144.82 /

-1.4 (-0.96%)

Hot Stocks
scPharmaceuticals falls 16% to $5.10 after announcing common stock offering  16:13
11/21/22
11/21
16:13
11/21/22
16:13
SCPH

scPharmaceuticals

$6.05 /

-0.27 (-4.27%)

 
ShowHide Related Items >><<
SCPH scPharmaceuticals
$6.05 /

-0.27 (-4.27%)

SCPH scPharmaceuticals
$6.05 /

-0.27 (-4.27%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
SCPH scPharmaceuticals
$6.05 /

-0.27 (-4.27%)

Syndicate
scPharmaceuticals files to sell common stock, no amount given » 16:03
11/21/22
11/21
16:03
11/21/22
16:03
SCPH

scPharmaceuticals

$6.08 /

-0.24 (-3.80%)

SVB Securities and Cowen…

SVB Securities and Cowen are acting as joint book-running managers for the Offering.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$6.08 /

-0.24 (-3.80%)

SCPH scPharmaceuticals
$6.08 /

-0.24 (-3.80%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
SCPH scPharmaceuticals
$6.08 /

-0.24 (-3.80%)

Recommendations
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright » 06:12
11/10/22
11/10
06:12
11/10/22
06:12
SCPH

scPharmaceuticals

$5.36 /

-0.27 (-4.80%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on scPharmaceuticals to $18 from $15 and keeps a Buy rating on the shares following the approval of Furoscix.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$5.36 /

-0.27 (-4.80%)

SCPH scPharmaceuticals
$5.36 /

-0.27 (-4.80%)

10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
10/11/22 SVB Securities
SVB Securities upgrades scPharmaceuticals to Outperform, raises target to $11
SCPH scPharmaceuticals
$5.36 /

-0.27 (-4.80%)

Over a month ago
Initiation
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies » 08:33
10/21/22
10/21
08:33
10/21/22
08:33
SCPH

scPharmaceuticals

$5.46 /

+0.22 (+4.20%)

As previously reported,…

As previously reported, Jefferies analyst Glen Santangelo initiated coverage of scPharmaceuticals with a Buy rating and $14 price target. He believes the "pieces are in place for strong adoption" of Furoscix ahead of an expected launch in Q1 of 2023, Santangelo tells investors. He expects payors to be receptive to covering the drug, helping drive his "above consensus" long-term estimates, the analyst noted.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$5.46 /

+0.22 (+4.20%)

SCPH scPharmaceuticals
$5.46 /

+0.22 (+4.20%)

10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
10/11/22 SVB Securities
SVB Securities upgrades scPharmaceuticals to Outperform, raises target to $11
10/11/22 SVB Securities
scPharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
SCPH scPharmaceuticals
$5.46 /

+0.22 (+4.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.